^
Association details:
| Biomarker: | FGF19 positive |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Cejemly (sugemalimab) (PD-L1 inhibitor) + fisogatinib (BLU-554) (FGFR4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma
Published date:
02/10/2023
Excerpt:
This Phase Ib/II trial enrolled patients with locally advanced or metastatic HCC who were FGF19-positive….The trial revealed a 50% ORR and 100% DCR….Preliminary data showed that BLU-554 in combination with CS1001 is safe and effective for treatment of patients with locally advanced or metastatic HCC.
DOI:
10.1007/s10637-023-01335-w
